DOCSLIB.ORG

Increasing Impact

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Increasing Impact INCREASING IMPACT 2010 Catalyst Annual Report PB 2010 CATALYST ANNUAL REPORT 2010 CATALYST ANNUAL REPORT A About Catalyst Founded in 1962, Catalyst is the leading nonprofit membership organization expanding opportunities for women and business. With offices in the United States, Canada, and Europe, and more than 400 preeminent corporations as members, Catalyst is the trusted resource for research, information, and advice about women at work. Catalyst annually honors exemplary organizational initiatives that promote women's advancement with the Catalyst Award. B 2010 CATALYST ANNUAL REPORT 2010 CATALYST ANNUAL REPORT 1 TABLE OF CONTENTS Letter From the President & CEO and Chair 2 Vision, Mission, Values 4 Impacting Inclusion 6 2010 Catalyst Highlights 6 Events 8 Catalyst in the News 11 Speaking Engagements 16 Catalyst on the Web 18 Inspiring With Insights 19 Knowledge Products 19 Advisory Services 22 E. L. Wiegand Foundation Grant 24 Engaging The Exceptional 27 Catalyst Awards Dinner 27 Catalyst Awards Conference 29 Catalyst Awards Dinner Contributors 30 The Catalyst Canada Honours 33 The Catalyst Canada Honours Contributors 35 Special Project Funding 37 Connecting Our Constituency 40 Catalyst Members 40 Financials and Notes to Consolidated Financial Statement 43 Catalyst Boards 50 B 2010 CATALYST ANNUAL REPORT 2010 CATALYST ANNUAL REPORT 1 LETTER FROM THE PRESIDENT & CEO AND CHAIR Connect. Engage. Inspire. Impact. Catalyst’s values reflect our organizational evolution as well as our growing role in the global workplace. In earlier times, Catalyst connected women with employers; we engaged corporations and the media in a dialogue about the issues women face in the workplace; and we inspired many individuals to action with our powerful research. In 2010, Catalyst worked to impact more people and more corporations in more locations than ever before. We influenced public policy We responded to the growing in new ways this year. Catalyst interest of our members’ leaders testified before the subsidiaries in India with Senates of three governments the publication of Leadership and advised government Gap in India Inc.: Myths and agencies of four countries on Realities. We launched The challenges related to advancing Catalyst Canada Honours to women onto corporate boards celebrate champions of women and closing the gender pay in Canadian business. And gap. Our important research we have developed our web series on high-potential women presence through social media in the corporate pipeline has tools and blogs. been published in three articles in the Harvard Business Review. 2 2010 CATALYST ANNUAL REPORT This work has already paid and corporations around the strengthening our reputation, dividends. Our membership world. We have stewarded knowledge, and ability to has increased to over 450 our corporate relationships make change across industries companies, firms, and to a new level, and our fiscal and cultures, they multiply educational institutions from responsibility over the past few our impact throughout their five continents; eight of decades has positioned us well powerful spheres of influence. these form an elite group of for the future. inaugural Research Sponsors, With thanks to everyone who committed to supporting our Our impact in 2010 and the has made 2010 a successful growing body of knowledge. impact we plan for the future year, we look forward to Our work and Catalyst experts would not be possible without connecting, engaging, were cited in the global media the considerable support of our inspiring, and impacting even 613 times, and we were asked members, board members, and more people in 2011. to speak at 54 conferences devoted staff. In addition to Ilene H. Lang James S. Turley President & Chief Executive Chairman & Chief Executive Officer Officer Ernst & Young Catalyst Chair, Catalyst Board of Directors “When you close your eyes and think of a leader, who do you see? Most people see men. This is the problem.” - Ilene Lang Catalyst on Twitter @CatalystInc 2010 CATALYST ANNUAL REPORT 3 VISION, MISSION, VALUES Anticipating our 50th anniversary, in 2010 Catalyst embarked on a strategic review to assess the opportunities and challenges of our third 25 years. At the same time, we more sharply framed our objectives and approaches. As a result, we have refreshed our vision, mission, and values—the cornerstones of our work, culture, and goals. OUR VISION Allow the men you Changing workplaces. know to see the world Changing lives. from your eyes. Share In the past, Catalyst often acted as an awareness- raising research organization that invited companies your experiences. It can to take action. Our new vision sees Catalyst as a driver of change—a true catalyst that impacts workplaces change their perspective, and lives around the world through research, events, practice-sharing, tools, social networking, and or even their lives. member engagement. Ilene H. Lang, Catalyzing www.catalyzing.org 4 2010 CATALYST ANNUAL REPORT OUR MISSION To help our members at each step Expanding opportunities for of this journey, every day we ask ourselves questions such as: women and business. The wording may have changed since 1962, but • How can we connect our Catalyst’s mission has always been to expand the members to each other and to employment opportunities available to women. At first, simply getting women into part-time jobs was us? the goal. Now, we focus on leveling the playing field in terms of advancement opportunities, leadership • How can we engage development, and compensation, and we advocate with women, men, families, for the inclusion of diverse women. As more women employers, economies, and become full participants in today’s workplaces, businesses benefit from their talent, creativity, and societies? leadership. • How can we inspire inclusion through our research, events, social media, speaking OUR VALUES engagements, and members? Connect, Engage, Inspire, • How can we positively Impact. impact workplaces and, therefore, lives? Catalyst’s values are the prism through which we filter our actions. They reflect our ethos, strengths, and objectives. They also reflect the evolution of our With our values guiding Catalyst members as they gain awareness of how diversity is through the next phase of connected to business success, implement programs and processes to engage and measure diverse aspects our future, and our members of the workforce, leverage new knowledge about their alongside us, we strive to workforce to inspire more significant change, and ultimately benefit from the positive impact of their accomplish our mission and focus on workplace inclusion. realize our vision. 2010 CATALYST ANNUAL REPORT 5 IMPACTING INCLUSION 2010 Catalyst Highlights Since 1962, Catalyst’s work has had a profound impact on innumerable women, men, corporations, and firms. Much of that impact was realized one woman, one CEO, or one company at a time. We still strive to build close individual relationships with others who share our mission, but we now aim to position our work strategically to drive impact on a larger scale—across workplaces, economies, and cultures. In 2010, Catalyst made its first forays into the public-policy arena. By testifying on issues such If all our daughters see as pay equity and women on corporate boards, Catalyst executives have helped government leaders understand how public policy affects working and hear is men, what women and the economy. For example, at a hearing titled “New Evidence on the Gender Pay Gap for does this tell them Women and Mothers in Management,” Catalyst President & CEO Ilene H. Lang testified before the U.S. Congress Joint Economic Committee about about themselves and new findings by Catalyst on corporate leadership and pay gaps. Two days later, The Hill, an influential congressional newspaper, published her op-ed on the their position in the same topic. world? Women must be Deborah Gillis, Senior Vice President, Membership & Global Operations, also appeared as an expert witness before the Canadian Senate Committee on visible. Everywhere. Banking, Trade and Commerce, to contribute to its consideration of proposed legislation to ensure Ilene H. Lang, Catalyzing women are appointed to a certain percentage of www.catalyzing.org 6 2010 CATALYST ANNUAL REPORT corporate board positions. In Europe, Catalyst representatives testified before the French Senate, worked with the labor ministries of both Spain and Norway, and advised the UK’s Government Equalities Office. All of these engagements were by invitation, highlighting the respect that Catalyst’s work has garnered in the public sector. As Catalyst’s reputation grows, so does our geographic reach. With one of the largest economies in the world, millions of educated working women, and a pressing talent gap, India presents an irresistible business opportunity for global and local corporations and women. Our first report focused on India, Leadership Gap in India Inc.: Myths and Realities, debuted in November and marked the start of a strategic expansion that will soon include a Catalyst office in India. It’s hard to believe, but it has already been ten years since we opened our Toronto office. We celebrated Catalyst Canada’s tenth anniversary with the launch of The Catalyst Canada Honours, which recognized three champions of women in Canadian business. The number of people who gathered to enjoy the festivities— Eleanor Tabi Haller-Jorden, General Manager, more than 500!—was a testament to the impact Catalyst Europe AG we have had in Canada. Lastly, Catalyst’s digital footprint continues to grow. We added several new features to our website, gained an entirely new intranet, and put our Information Center’s catalog online. Social networking tools such as Facebook, Twitter, YouTube, and LinkedIn are now an integral part of our communications strategies, as are the two blogs we launched this year. No matter where you are, you can connect with Catalyst! 2010 CATALYST ANNUAL REPORT 7 Events 42 EVENTS 24 WEBINARS 2,250 WEBINAR PARTICIPANTS 600 EVENT ATTENDEES Catalyst’s events are central to our mission of Making Mentoring Work disseminating the research and knowledge that is January 19 at the core of our work.
Load more

Recommended publications
  • In the United States District Court for the District Of
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC and ) FOREST LABORATORIES ) HOLDINGS, LTD., ) ) Plaintiffs, ) ) v. ) Civ.No.14-1119-SLR ) SIGMAPHARM LABORATORIES, LLC, ) et al., ) ) Defendants. ) Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware. Counsel for Plaintiffs. Of Counsel: Howard W. Levine, Esquire, Sanya Sukduang, Esquire, Jonathan R. Davies, Esquire, Courtney B. Gasp, Esquire, and Charles E. Lipsey, Esquire of Finnegan, Henderson, Farabow, Garrett & Dunner LLP. John C. Phillips, Esquire, David A. Bilson, Esquire and Megan C. Haney of Phillips, Goldman, Mclaughlin & Hall, P.A., Wilmington, Delaware. Counsel for Defendant Sigmapharm Laboratories, LLC. Of Counsel: Anthony G. Simon, Esquire, Anthony R. Friedman, Esquire, Benjamin R. Askew, Esquire, and Michael P. Kella, Esquire of The Simon Law Firm, P.C. Karen Elizabeth Keller, Esquire and Jeffrey Thomas Castellano, Esquire of Shaw Keller, LLP, Wilmington, Delaware. Counsel for Defendants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, and West-Ward Pharmaceutical Corp. Of Counsel: lmron T. Aly, Esquire, Joel M. Wallace, Esquire, and Helen H. Ji, Esquire of Schiff Hardin LLP. Richard D. Kirk, Esquire, Stephen B. Brauerman, Esquire and Sara E. Bussiere, Esquire of Bayard, P.A., Wilmington, Delaware. Counsel for Defendant Breckenridge Pharmaceutical, Inc. Of Counsel: Beth D. Jacob, Esquire, Clifford Katz, Esquire, and Malavika A. Rao, Esquire of Kelley, Drye & Warren LLP. Karen Pascale, Esquire and Pilar G. Kraman, Esquire of Young, Conaway, Stargatt & Taylor, LLP, Wilmington, Delaware. Counsel for Defendants Alembic Pharmaceuticals Ltd., Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. Of Counsel: Steven J. Lee, Esquire, Michael K.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • Developments with Microsoft's New Windows 8 System 26 June 2013, by the Associated Press
    Developments with Microsoft's new Windows 8 system 26 June 2013, by The Associated Press The launch of Windows 8 was heralded as the — Nov. 28: Microsoft says about 40 million licenses biggest change to the industry's dominant to Windows 8 were sold in its first month on the operating system in at least 17 years. It attempts to market, though that number includes licenses bridge the gap between personal computers and bought by PC manufacturers for machines built but fast-growing tablets with its touch-enabled not yet sold. Microsoft didn't provide further details interface. But consumer reaction has been beyond saying that Windows 8 is being embraced lackluster. Microsoft now plans an update this year. by a list of companies that include Johnson & Johnson, British Telecom and Bank of America Corp. Here's a look at events surrounding Microsoft Corp .'s new system: — Nov. 29: NPD Group says sales of personal computers in the U.S. didn't get any boost from the — Oct. 25, 2012: Microsoft holds a launch event in launch of Windows 8. There's no sign that Windows New York for Windows 8, a major overhaul of its 8 made things worse for PC makers. Rather, NPD ubiquitous computer operating system. Not much says the weak sales are a continuation of a trend new is revealed, as many of the details had been seen throughout this year. announced before, and the software had been available for testing. — Jan. 8, 2013: Microsoft says it has sold 60 million Windows 8 licenses to date.
    [Show full text]
  • View Annual Report
    TO OUR SHAREHOLDERS, CUSTOMERS, PARTNERS AND EMPLOYEES: This is a unique letter for me – the last shareholder letter I will write as the CEO of the company I love. We have always believed that technology will unleash human potential and that is why I have come to work every day with a heart full of passion for more than 30 years. Fiscal Year 2013 was a pivotal year for Microsoft in every sense of the word. Last year in my letter to you I declared a fundamental shift in our business to a devices and services company. This transformation impacts how we run the company, how we develop new experiences, and how we take products to market for both consumers and businesses. This past year we took the first big bold steps forward in our transformation and we did it while growing revenue to $77.8 billion (up 6 percent). In addition, we returned $12.3 billion (up 15 percent) to shareholders through dividends and stock repurchases. While we were able to grow revenue to a record level, our earnings results reflect investments as well as some of the challenges of undertaking a transformation of this magnitude. With this as backdrop, I’d like to summarize where we are now and where we’re headed, because it helps explain why I’m so enthusiastic about the opportunity ahead. Our strategy: High-value activities enabled by a family of devices and services We are still in the early days of our transformation, yet we made strong progress in the past year launching devices and services that people love and businesses need.
    [Show full text]
  • United States District Court for the District of Columbia
    Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 1 of 49 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ASTRAZENECA PHARMACEUTICALS LP, Plaintiff, v. Civil Action No. 12-00472 (BAH) Judge Beryl A. Howell FOOD AND DRUG ADMINISTRATION, et al., Defendants. AMENDED MEMORANDUM OPINION Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) has manufactured the drug quetiapine fumarate (“quetiapine”) under the brand name Seroquel® (“Seroquel”) since 1997 without generic competition. AstraZeneca brought this lawsuit, which presents a question of statutory interpretation, against the Food and Drug Administration, Margaret A. Hamburg, M.D., Commissioner of Food and Drugs, and Kathleen Sebelius, Secretary of Health and Human Services (collectively, “the FDA”), to challenge the FDA’s approval, on March 27, 2012, of generic versions of Seroquel. See Complaint, ECF No. 1 (“Compl.”), ¶ 3. AstraZeneca believes that, under the plain language of 21 U.S.C. § 355(j)(5)(F)(iv), codifying Section 505(j)(5)(F)(iv) of the Federal Food, Drug, and Cosmetic Act (“FDCA”), it is entitled to total market exclusivity until December 2, 2012 for the safety information encapsulated in “Table 2,” which was approved for all Seroquel labels on December 2, 2009 and must be included on the labels of all generic versions of quetiapine. Based upon this belief, AstraZeneca seeks a judgment that the FDA’s recent approval of generic versions of quetiapine, while AstraZeneca retains exclusivity over Table 2, violated AstraZeneca’s exclusivity rights and was arbitrary, capricious, and contrary to law. 1 Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 2 of 49 Pending before the Court are Cross-Motions for Summary Judgment filed by AstraZeneca, ECF No.
    [Show full text]
  • Cephalon Provigil
    r* jfS* 1 ll JS 44 {Rev. 07/16) SHEET The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose ofinitiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.) 1. (a) PLAINTIFFS DEFENDANTS State of New York, et al. Cephalon, Inc. et al. (b) County of Residence of First Listed Plaintiff County of Residence of First Listed Defendant (EXCEPT IN U.S. PLAINTIFF CASES) (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED. (c) Attorneys (Firm Name, Address, and Telephone Number) Attorneys (If Known) Office of the Attorney General, Commonwealth of Pennsylvania, 14® Floor Jay Lefkowitz, Kirkland & Ellis, 601 Lexington Avenue, New York, NY 10022 Strawberry Square, Harrisburg, PA 17120(717)787-4530 (212)446-4800 II. BASIS OF JURISDICTION (Placean "X" in One Box Only) III. CITIZENSHIP OF PRINCIPAL PARTIES (Placean "X" inOne Box for Plaintiff (For Diversify Cases Only) and One Box for Defendant) • 1 U.S. Government ^ 3 Federal Question PTF DEF PTF DEF Plaintiff (U.S. Government Not a Party) Citizen of This State Q 1 • 1 Incorporated or Principal Place Q 4 HI 4 of Business In This State l~l 2 U.S. Government • 4 Diversity Citizen of Another State • 2 Q 2 Incorporated and Principal Place G 5 Q 5 Defendant (Indicate Citizenship of Parties in Item III) of Business In Another State Citizen or Subject of a Q3 D 3 Foreign Nation D 6 06 Foreign Country IV.
    [Show full text]
  • Constituents & Weights
    2 FTSE Russell Publications 19 August 2021 FTSE 100 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Group 0.59 UNITED GlaxoSmithKline 3.7 UNITED RELX 1.88 UNITED KINGDOM KINGDOM KINGDOM Admiral Group 0.35 UNITED Glencore 1.97 UNITED Rentokil Initial 0.49 UNITED KINGDOM KINGDOM KINGDOM Anglo American 1.86 UNITED Halma 0.54 UNITED Rightmove 0.29 UNITED KINGDOM KINGDOM KINGDOM Antofagasta 0.26 UNITED Hargreaves Lansdown 0.32 UNITED Rio Tinto 3.41 UNITED KINGDOM KINGDOM KINGDOM Ashtead Group 1.26 UNITED Hikma Pharmaceuticals 0.22 UNITED Rolls-Royce Holdings 0.39 UNITED KINGDOM KINGDOM KINGDOM Associated British Foods 0.41 UNITED HSBC Hldgs 4.5 UNITED Royal Dutch Shell A 3.13 UNITED KINGDOM KINGDOM KINGDOM AstraZeneca 6.02 UNITED Imperial Brands 0.77 UNITED Royal Dutch Shell B 2.74 UNITED KINGDOM KINGDOM KINGDOM Auto Trader Group 0.32 UNITED Informa 0.4 UNITED Royal Mail 0.28 UNITED KINGDOM KINGDOM KINGDOM Avast 0.14 UNITED InterContinental Hotels Group 0.46 UNITED Sage Group 0.39 UNITED KINGDOM KINGDOM KINGDOM Aveva Group 0.23 UNITED Intermediate Capital Group 0.31 UNITED Sainsbury (J) 0.24 UNITED KINGDOM KINGDOM KINGDOM Aviva 0.84 UNITED International Consolidated Airlines 0.34 UNITED Schroders 0.21 UNITED KINGDOM Group KINGDOM KINGDOM B&M European Value Retail 0.27 UNITED Intertek Group 0.47 UNITED Scottish Mortgage Inv Tst 1 UNITED KINGDOM KINGDOM KINGDOM BAE Systems 0.89 UNITED ITV 0.25 UNITED Segro 0.69 UNITED KINGDOM
    [Show full text]
  • Small Business Offensive Tom Healy Is Spearheading Best Buy’S Push Into Small Business Sales
    0606rcp_cover 5/9/06 4:32 PM Page 1 ChannelRedmond Partnerwww.rcpmag.com ■ June 2006 DRIVING SUCCESS IN THE MICROSOFT PARTNER COMMUNITY Honored as BEST START-UP PUBLICATION Jesse H. Neal National Business Journalism Awards 2006 Best Buy’s Small Business Offensive Tom Healy is spearheading Best Buy’s push into small business sales. Can partners handle the competition? 22 +Going Gold: Worth the Effort? 30 A Dynamic Approach to ERP 36 Make Specialization Work for You 42 Project8 5/3/06 4:05 PM Page 1 Project8 5/3/06 4:06 PM Page 2 Project1 5/3/06 11:22 AM Page 1 0606rcp_TOC_1.v7 5/9/06 4:21 PM Page 1 Redmond ChannelPartnerJune 2006 DRIVING SUCCESS IN THE MICROSOFT PARTNER COMMUNITY FEATURES DEPARTMENTS 42 36 22 Best Buy’s Small-Business Offensive In a move that’s making some Microsoft partners jittery, the retail giant plans to double the number of stores targeting SMBs this year. 14 30 Going for the Gold 4 PARTNER POINTS 22 Making the jump from Certified to Gold License management issues addressed and suggestions Certified is worth the effort—but not necessarily offered; a defense for Software as a Service; a reader for the reasons Redmond emphasizes. expands his prospects with inside information 6 CHANNEL REPORT 36 Getting Serious About ERP Support deadline looms for Windows 98/SE/Me . 6 Microsoft is getting serious about Dynamics, Piracy in China tempers business opportunities . 8 and partners should, too. Microsoft Partner Calendar . 9 Microsoft earnings a mixed bag for partners . 10 30 42 One Hat or Many? ANATOMY OF THE DEAL: Microsoft-Hyperion Solutions .
    [Show full text]
  • Global Focus – Economic Outlook Q2-2021
    Global Research Global Focus – Economic Outlook Q2-2021 Global growth – An uneven race research.sc.com Standard Chartered Global Research is available across all iOS and Android devices. Our intuitive, accessible and customisable apps* allow you to receive our reports, forecasts, audio-visual presentations and interactive data visualisation tools on-the-go. * Click the icons to download or search ‘Standard Chartered Global Research’ in the app store. If you are in scope for MiFID II and want to opt out of our Research services, please contact us. Issuer of Report Standard Chartered Bank Important disclosures and analyst certifications can be found in the Disclosures Appendix All rights reserved. Standard Chartered Bank 2021 https://research.sc.com Global Focus – Economic Outlook Q2-2021 Table of contents Global overview 3 Cameroon – Moving towards recovery 75 Global growth – An uneven race 4 Côte d’Ivoire – A series of unfortunate events 76 Where we differ from consensus 10 Ethiopia – A particularly difficult quarter ahead 77 Global charts 12 Gabon – The oil price reprieve 78 Ghana – The long reach of the COVID crisis 79 Geopolitical economics 14 Kenya – Third-wave woes 80 Biden’s democracy club 15 Mozambique – Delayed but not denied 81 Economies – Asia 20 Nigeria – Higher oil, faltering reform 82 Asia – Top charts 21 Senegal – Flaring tensions 83 Asia – Macro trackers 22 South Africa – Bracing for a third wave 84 Australia – Chugging along 24 Tanzania – Transition 86 Bangladesh – Turning around 26 Uganda – Oil to drive growth acceleration
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]